表紙
市場調査レポート

2017年までの免疫調節薬市場―最も高価値の分野として2017年までに代謝拮抗物質に取って変わる免疫抑制抗体

Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017

発行 GBI Research 商品コード 230025
出版日 ページ情報 英文 290 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
2017年までの免疫調節薬市場―最も高価値の分野として2017年までに代謝拮抗物質に取って変わる免疫抑制抗体 Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017
出版日: 2012年02月01日 ページ情報: 英文 290 Pages
概要

当レポートは、米国および欧州をはじめとする各地域の免疫調節薬市場について調査分析し、2017年までの免疫調節薬の研究開発パイプラインや販売予測、競争環境、地域別の展望などについてまとめ、概略下記の内容でお届けするものです。

目次

第1章 目次

第2章 2017年までの免疫調節薬市場―イントロダクション

  • GBI調査報告書に関するガイダンス

第3章 2017年までの免疫調節薬市場―市場の特徴

  • 分類
  • 成長促進要因と阻害要因
  • 世界的な市場の成長促進要因
  • 世界的な市場の成長阻害要因
  • 満たされていないニーズ
  • 収益予測―世界

第4章 2017年までの免疫調節薬市場―各地域の展望

  • 米国
  • 欧州
  • その他地域

第5章 2017年までの免疫調節薬市場―免疫抑制剤

第6章 免疫抑制剤―抗体

第7章 免疫抑制剤―インターフェロン・ベータ

第8章 免疫抑制剤―グルココルチコイド

第9章 免疫抑制剤―カルシニューリン阻害剤

第10章 免疫抑制剤―代謝拮抗物質

第11章 2017年までの免疫調節薬市場―免疫刺激剤

第12章 免疫刺激剤―ワクチン、能動免疫

第13章 免疫刺激剤:抗体―受動免疫

第14章 免疫刺激剤:インターフェロン・アルファ―受動免疫

第15章 2017年までの免疫調節薬市場―競争環境

第16章 2017年までの免疫調節薬市場―戦略的合併

第17章 付録

目次

Summary

GBI Research analysis estimated the global immunomodulators market to be valued at $145.9 billion in 2010, with a Compound Annual Growth Rate (CAGR) of 13.1% between 2002 and 2010. The market is forecast to grow at a CAGR of 8.6% between 2010 and 2017, to reach $259.3 billion in 2017. In-depth analysis in the report is based on propriety databases, primary and secondary research and in-house analysis by the GBI Research team of experts.

GBI Research analysis found the R&D pipeline for the immunomodulators market to be strong. Many of the major pharmaceutical companies such as Roche, Amgen, and Johnson & Johnson are expanding into this market. This indicates that R&D activity for immunomodulators will remain active for at least next four to five years.

Scope

  • Data and analysis of the immunomodulators market in the leading geographies of the US and Europe. Different drug classes of immunomodulators discussed in the report are immunosuppressants (antibodies, interferon beta, glucocorticoids, calcineurin inhibitors, antimetabolites) and immunostimulants (antibodies, interferon alpha and vaccines).
  • Annualized market data for the immunomodulators market from 2002 to 2010, with forecasts to 2017.
  • Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and sales volumes
  • Key drivers and restraints that have had significant impact on the market.
  • Competitive landscape of the global immunomodulators market including benchmarking of the top companies. The key companies studied in this report are Hoffman La Roche, Amgen, Abbott, Johnson & Johnson, Novartis, Biogen Idec, Merck, Bristol-Myers Squibb, Eli Lilly.

Reasons to buy

  • Build effective strategies to launch pipeline products, by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products to fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of the top competitors.
  • Develop market-entry and market expansion strategies, by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with improved efficacy and safety profiles.

Executive Summary

Leading business intelligence provider GBI Research has released its latest research report, “Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017”, which provides insight about immunomodulators sales forecasts until 2017.I Immunomodulators markets in the key geographies of the US, Europe and other relevant regions are also covered in the report, as are immunomodulators R&D pipelines. The report provides in-depth analysis and market forecasts of the major drug classes, which include immunosuppressants (antibodies, interferon beta, glucocorticoids, calcineurin inhibitors, and antimetabolites), and immunostimulants (antibodies, interferon alpha and vaccines). The report also explores the competitive landscape, with a competitive analysis of the top companies in the market.

Immunosuppressants holds a 64% Market Share of the Immunomodulators Market with More Products in the Pipeline than Immunostimulants

Immunosuppressants generated revenues of $92.2 billion in 2010 while immunostimulants generated revenues of $53.7 billion. There are more classes of immunosuppressants than immunostimulants because it is difficult to boost the cells of the immune system as they all respond to antigens in different ways. The immunostimulants market is estimated to grow at a Compound Annual Growth Rate (CAGR) of 10.5% and the immunosuppressants market is forecast to grow at a CAGR of 7.3%, although there are more products in the pipeline for immunosuppressants. Immunostimulatory Monoclonal Antibodies (mAbs) such as cancer antibodies and vaccines will contribute most to the growth of the markets as there is a great deal of scope for these classes in the oncology market, valued at $60.5 billion in 2010.

Antimetabolic Drugs Generated the Highest Revenues of all Classes of Immunomodulators

Antiproliferative and antimetabolic drugs generated revenues of approximately $33.2 billion in 2010. However, with the gradual approval of mAbs as first-line treatment, antiproliferative and antimetabolic drugs will grow at a comparatively slow rate. Conventional therapy, namely chemotherapy, has a long history of poor safety profiles due to systemic action characteristics, which means its often fails to impart the desired effect at the site of action. Cancer is better managed with personalized oncological treatments such as measuring erbB2 (erythroblastic leukemia viral oncogene homolog 2) and EGFR (Epidermal Growth Factor Receptor) proteins in breast, lung and colorectal cancer patients before selecting suitable treatments. Herceptin is used in the treatment of women with breast cancer in which HER2 (Human Epidermal growth factor Receptor 2) protein is overexpressed.

Antibodies Market Forecast to show Highest Growth Rate of all Classes of Immunomodulators

Antibodies were the fastest growing segment in the global immunomodulators market in 2010. The global antibodies market was worth $51.8 billion in 2010, comprising mAbs and fusion proteins. Antibodies are used in a range of oncology indications and autoimmune diseases. In 2010, immunostimulating antibodies generated revenues of $23 billion while immunosuppressive antibodies generated $28.8 billion. Mabs are gradually moving into the treatment of Central Nervous System (CNS) disorders such as Alzheimer's disease and metabolic disorders such as diabetes. The first therapeutic mAb approved by the Food and Drug Administration (FDA) was Muromonab-CD3 (trade name Orthoclone OKT3), a murine IgG2a CD3 specific transplant rejection drug, also known as muromonab. It was approved in 1986 and was used in steroid-resistant solid organ transplant recipients. Since the launch of Orthoclone OKT3 in 1992, 30 mAbs have been launched globally. Of these, three have been discontinued due to safety issues. Successful mAbs such as rituxan, avastin and remicade have received regulatory approvals for multiple indications, further increasing the patient base.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Immunomodulators Market to 2017 - Market Introduction

  • 2.1. GBI Research Report Guidance

3. Immunomodulators Market to 2017 - Market Characterization

  • 3.1. Classification
  • 3.2. Drivers and Barriers
  • 3.3. Global Immunomodulators Market Drivers
  • 3.4. Global Immunomodulators Market Restraints
  • 3.5. Unmet Needs
  • 3.6. Revenue Forecast - Global

4. Immunomodulators Market to 2017 - Geographical Landscape

  • 4.1. The US
  • 4.2. Europe
  • 4.3. ROW

5. Immunomodulators Market to 2017 - Immunosuppressants

  • 5.1. Introduction
  • 5.2. Drug Classes
  • 5.3. Applications
  • 5.4. Global Market Size

6. Immunosuppressants - Antibodies

  • 6.1. Introduction
  • 6.2. Prescription Population
  • 6.3. Annual Cost of Therapy
  • 6.4. Revenue
  • 6.5. Pipeline Molecules

7. Immunosuppressants - Interferon Beta

  • 7.1. Introduction
  • 7.2. Prescription Population
  • 7.3. Annual Cost of Therapy
  • 7.4. Revenue
  • 7.5. Pipeline Molecules

8. Immunosuppressants - Glucocorticoids

  • 8.1. Introduction
  • 8.2. Therapeutic Indications
  • 8.3. Immunological Mode of Action
  • 8.4. Prescription Population
  • 8.5. Annual Cost of Therapy
  • 8.6. Revenue
  • 8.7. Pipeline Molecules

9. Immunosuppressants - Calcineurin Inhibitors

  • 9.1. Introduction
  • 9.2. Prescription Population
  • 9.3. Annual Cost of Therapy
  • 9.4. Revenue
  • 9.5. Pipeline Molecules

10. Immunosuppressants - Antimetabolites

  • 10.1. Introduction
  • 10.2. Prescription Population
  • 10.3. Annual Cost of Therapy
  • 10.4. Revenue
  • 10.5. Pipeline Molecules

11. Immunomodulators Market to 2017 - Immunostimulants

  • 11.1. Introduction
  • 11.2. Drug Classes
  • 11.3. Applications
  • 11.4. Global Market Size

12. Immunostimulants - Vaccines, Active Immunity

  • 12.1. Introduction
  • 12.2. Target Population
  • 12.3. Revenue
  • 12.4. Pipeline Molecules

13. Immunostimulants: Antibodies - Passive Immunity

  • 13.1. Introduction
  • 13.2. Prescription Population
  • 13.3. Annual Cost of Therapy
  • 13.4. Revenue
  • 13.5. Pipeline Molecules

14. Immunostimulants: Interferon Alpha - Passive Immunity

  • 14.1. Introduction
  • 14.2. Prescription Population
  • 14.3. Annual Cost of Therapy
  • 14.4. Revenue
  • 14.5. Pipeline Molecules

15. Immunomodulators Market to 2017 - Competitive Landscape

  • 15.1. Market Share Analysis
  • 15.2. Hoffmann-La Roche Ltd Roche
  • 15.3. Amgen Inc
  • 15.4. Abbott Laboratories
  • 15.5. Johnson & Johnson
  • 15.6. Novartis AG
  • 15.7. Biogen Idec
  • 15.8. Merck & Co Inc
  • 15.9. Bristol Myers Squibb Company
  • 15.10. Eli Lilly and Company

16. Immunomodulators Market to 2017 - Strategic Consolidations

  • 16.1. M&A Deals by Type
  • 16.2. M&A Landscape
  • 16.3. Major Deals
  • 16.4. Licensing Deals
  • 16.5. Major Deals
  • 16.6. Partnership Deals
  • 16.7. Major Deals

17. Immunomodulators Market to 2017 - Appendix

  • 17.1. Market Definitions
  • 17.2. Abbreviations
  • 17.3. Research Methodology
  • 17.4. Therapeutic Landscape
  • 17.5. Geographical Landscape
  • 17.6. Pipeline Analysis
  • 17.7. Competitive Landscape
  • 17.8. Contact Us
  • 17.9. Disclaimer
  • 17.10. Sources

List of Tables

  • Table 1: Immunomodulators Market to 2017, Global, Revenue ($bn), 2002-2010
  • Table 2: Immunomodulators Market to 2017, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 3: Immunomodulators Market to 2017, Global, Annual Cost of Therapy ($), 2002-2010
  • Table 4: Immunomodulators Market to 2017, Global, Annual Cost of Therapy ($), 2010-2017
  • Table 5: Immunomodulators Market to 2017, Global, Prescription Population (million), 2002-2010
  • Table 6: Immunomodulators Market to 2017, Global, Prescription Population (million), 2010-2017
  • Table 7: Immunomodulators Market to 2017, The US, Revenue ($bn), 2002-2010
  • Table 8: Immunomodulators Market to 2017, The US, Revenue Forecasts (bn), 2010-2017
  • Table 9: Immunomodulators Market to 2017, Europe, Revenue ($bn), 2002-2010
  • Table 10: Immunomodulators Market to 2017, Europe, Revenue Forecasts ($bn), 2010-2017
  • Table 11: Immunomodulators Market to 2017, ROW, Revenue ($bn), 2002-2010
  • Table 12: Immunomodulators Market to 2017, ROW, Revenue Forecasts ($bn), 2010-2017
  • Table 13: Immunomodulators Market to 2017, Immunosuppressants, Global, Revenue ($bn), 2002-2010
  • Table 14: Immunomodulators Market to 2017, Immunosuppressants, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 15: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Prescription Population (million), 2002-2010
  • Table 16: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Prescription Population (million), 2010-2017
  • Table 17: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Prescription Population (million), 2002-2010
  • Table 18: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Prescription Population (million), 2010-2017
  • Table 19: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Prescription Population (million), 2002-2010
  • Table 20: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Prescription Population (million), 2010-2017
  • Table 21: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Prescription Population (million), 2002-2010
  • Table 22: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Prescription Population (million), 2010-2017
  • Table 23: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Annual Cost of Therapy ($), 2002-2010
  • Table 24: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Annual Cost of Therapy ($), 2010-2017
  • Table 25: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Annual Cost of Therapy ($), 2002-2010
  • Table 26: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Annual Cost of Therapy ($), 2010-2017
  • Table 27: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Annual Cost of Therapy ($), 2002-2010
  • Table 28: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Annual Cost of Therapy ($), 2010-2017
  • Table 29: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Annual Cost of Therapy ($), 2002-2010
  • Table 30: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Annual Cost of Therapy ($), 2010-2017
  • Table 31: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Revenue ($bn), 2002-2010
  • Table 32: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 33: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Revenue ($bn), 2002-2010
  • Table 34: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Revenue Forecasts ($bn), 2010-2017
  • Table 35: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Revenue ($bn), 2002-2010
  • Table 36: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Revenue Forecasts ($bn), 2010-2017
  • Table 37: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Revenue ($bn), 2002-2010
  • Table 38: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Revenue Forecasts ($bn), 2010-2017
  • Table 39: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Pipeline Molecules, Phase III, 2011
  • Table 40: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Pipeline Molecules, Phase II, 2011
  • Table 41: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Pipeline Molecules, Phase I, 2011
  • Table 42: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Pipeline Molecules, Preclinical/Discovery Phase, 2011
  • Table 43: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Prescription Population (million), 2002-2010
  • Table 44: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Prescription Population (million), 2010-2017
  • Table 45: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US, Prescription Population, 2002-2010
  • Table 46: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US, Prescription Population, 2010-2017
  • Table 47: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Prescription Population, 2002-2010
  • Table 48: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Prescription Population, 2010-2017
  • Table 49: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Prescription Population, 2002-2010
  • Table 50: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Prescription Population, 2010-2017
  • Table 51: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Annual Cost of Therapy ($), 2002-2010
  • Table 52: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Annual Cost of Therapy ($), 2010-2017
  • Table 53: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US Annual Cost of Therapy ($), 2002-2010
  • Table 54: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US Annual Cost of Therapy ($), 2010-2017
  • Table 55: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Annual Cost of Therapy ($), 2002-2010
  • Table 56: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Annual Cost of Therapy ($), 2010-2017
  • Table 57: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Annual Cost of Therapy ($), 2002-2010
  • Table 58: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Annual Cost of Therapy ($), 2010-2017
  • Table 59: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Revenue ($bn), 2002-2010
  • Table 60: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 61: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US, Revenue ($bn), 2002-2010
  • Table 62: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US, Revenue Forecasts ($bn), 2010-2017
  • Table 63: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Revenue ($bn), 2002-2010
  • Table 64: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Revenue Forecasts ($bn), 2010-2017
  • Table 65: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Revenue ($bn), 2002-2010
  • Table 66: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Revenue Forecasts ($bn), 2010-2017
  • Table 67: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Pipeline Molecules, Phase III, 2011
  • Table 68: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Pipeline Molecules, Phase II, 2011
  • Table 69: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Pipeline Molecules, Phase I, 2011
  • Table 70: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Pipeline Molecules, Preclinical/Discovery Phase, 2011
  • Table 71: Immunomodulators Market to 2017, Comparative Glucocorticoid Potency, 2011
  • Table 72: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Prescription Population (million), 2002-2010
  • Table 73: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Prescription Population (million), 2010-2017
  • Table 74: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Prescription Population (million), 2002-2010
  • Table 75: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Prescription Population (million), 2010-2017
  • Table 76: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Prescription Population (million), 2002-2010
  • Table 77: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Prescription Population (million), 2010-2017
  • Table 78: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Prescription Population (million), 2002-2010
  • Table 79: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Prescription Population (million), 2010-2017
  • Table 80: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Annual Cost of Therapy ($), 2002-2010
  • Table 81: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Annual Cost of Therapy ($), 2010-2017
  • Table 82: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Annual Cost of Therapy ($), 2002-2010
  • Table 83: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Annual Cost of Therapy ($), 2010-2017
  • Table 84: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Annual Cost of Therapy ($), 2002-2010
  • Table 85: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Annual Cost of Therapy ($), 2010-2017
  • Table 86: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Annual Cost of Therapy ($), 2002-2010
  • Table 87: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Annual Cost of Therapy ($), 2010-2017
  • Table 88: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Revenue ($bn), 2002-2010
  • Table 89: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 90: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Revenue ($bn), 2002-2010
  • Table 91: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Revenue Forecasts ($bn), 2010-2017
  • Table 92: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Revenue ($bn), 2002-2010
  • Table 93: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Revenue Forecasts ($bn), 2010-2017
  • Table 94: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Revenue ($bn), 2002-2010
  • Table 95: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Revenue Forecasts ($bn), 2010-2017
  • Table 96: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Pipeline Molecules, Phase III, 2011
  • Table 97: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Pipeline Molecules, Phase II, 2011
  • Table 98: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Pipeline Molecules, Phase I, 2011
  • Table 99: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Pipeline Molecules, Preclinical/Discovery Phase, 2011
  • Table 100: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Prescription Population, 2002-2010
  • Table 101: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Prescription Population, 2010-2017
  • Table 102: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Prescription Population, 2002-2010
  • Table 103: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Prescription Population, 2010-2017
  • Table 104: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Prescription Population, 2002-2010
  • Table 105: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Prescription Population, 2010-2017
  • Table 106: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Prescription Population, 2002-2010
  • Table 107: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Prescription Population, 2010-2017
  • Table 108: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Annual Cost of Therapy ($), 2002-2010
  • Table 109: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Annual Cost of Therapy ($), 2010-2017
  • Table 110: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Annual Cost of Therapy ($), 2002-2010
  • Table 111: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Annual Cost of Therapy ($), 2010-2017
  • Table 112: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Annual Cost of Therapy ($), 2002-2010
  • Table 113: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Annual Cost of Therapy ($), 2010-2017
  • Table 114: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Annual Cost of Therapy ($), 2002-2010
  • Table 115: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Annual Cost of Therapy ($), 2010-2017
  • Table 116: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Revenue ($bn), 2002-2010
  • Table 117: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 118: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Revenue ($bn), 2002-2010
  • Table 119: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Revenue Forecasts ($bn), 2010-2017
  • Table 120: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Revenue ($bn), 2002-2010
  • Table 121: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Revenue Forecasts ($bn), 2010-2017
  • Table 122: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Revenue ($bn), 2002-2010
  • Table 123: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Revenue Forecasts ($bn), 2010-2017
  • Table 124: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Pipeline Analysis, Phase III, 2011
  • Table 125: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Pipeline Analysis, Phase II, 2011
  • Table 126: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Pipeline Analysis, Phase I, 2011
  • Table 127: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Pipeline Analysis, Preclinical/Discovery Phase, 2011
  • Table 128: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Prescription Population (million), 2002-2010
  • Table 129: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Prescription Population (million), 2010-2017
  • Table 130: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Prescription Population (million), 2002-2010
  • Table 131: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Prescription Population (million), 2010-2017
  • Table 132: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Prescription Population (million), 2002-2010
  • Table 133: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Prescription Population (million), 2010-2017
  • Table 134: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Prescription Population (million), 2002-2010
  • Table 135: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Prescription Population (million), 2010-2017
  • Table 136: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Annual Cost of Therapy ($), 2002-2010
  • Table 137: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Annual Cost of Therapy ($), 2010-2017
  • Table 138: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Annual Cost of Therapy ($), 2002-2010
  • Table 139: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Annual Cost of Therapy ($), 2010-2017
  • Table 140: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Annual Cost of Therapy ($), 2002-2010
  • Table 141: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Annual Cost of Therapy ($), 2010-2017
  • Table 142: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Annual Cost of Therapy ($), 2002-2010
  • Table 143: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Annual Cost of Therapy ($), 2010-2017
  • Table 144: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Revenue ($bn), 2002-2010
  • Table 145: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 146: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Revenue ($bn), 2002-2010
  • Table 147: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Revenue Forecasts ($bn), 2010-2017
  • Table 148: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Revenue ($bn), 2002-2010
  • Table 149: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Revenue Forecasts ($bn), 2010-2017
  • Table 150: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Revenue ($bn), 2002-2010
  • Table 151: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Revenue Forecasts ($bn), 2010-2017
  • Table 152: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites Pipeline Molecules, Phase III, 2011
  • Table 153: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites Pipeline Molecules, Phase II, 2011
  • Table 154: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites Pipeline Molecules, Phase I, 2011
  • Table 155: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites Pipeline Molecules, Preclinical/Discovery Phase, 2011
  • Table 156: Immunomodulators Market to 2017, Immunostimulants, Revenue ($bn), 2002-2010
  • Table 157: Immunomodulators Market to 2017, Immunostimulants, Revenue Forecasts ($bn), 2010-2017
  • Table 158: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Vaccine Preventable Disease, 2010
  • Table 159: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Target Pediatric and Adult Population ('000), 2002-2010
  • Table 160: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Target Pediatric and Adult Population ('000), 2010-2017
  • Table 161: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Revenue ($bn), 2002-2010
  • Table 162: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 163: Immunomodulators Market to 2017, Immunostimulants, Vaccines, The US, Revenue ($bn), 2002-2010
  • Table 164: Immunomodulators Market to 2017, Immunostimulants, Vaccines, The US, Revenue Forecasts ($bn), 2010-2017
  • Table 165: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Europe, Revenue ($bn), 2002-2010
  • Table 166: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Europe, Revenue Forecasts ($bn), 2010-2017
  • Table 167: Immunomodulators Market to 2017, Immunostimulants, Vaccines, ROW, Revenue ($bn), 2002-2010
  • Table 168: Immunomodulators Market to 2017, Immunostimulants, Vaccines, ROW, Revenue Forecasts ($bn), 2010-2017
  • Table 169: Immunomodulators Market to 2017, Immunostimulants, Vaccines, NDA Filed Molecules, 2011
  • Table 170: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Pipeline Molecules, Phase III, 2011
  • Table 171: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Pipeline Molecules, Phase II, 2011
  • Table 172: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Pipeline Molecules, Phase I, 2011
  • Table 173: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Pipeline Molecules, Preclinical/Discovery Phase, 2011
  • Table 174: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Prescription Population (million), 2002-2010
  • Table 175: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Prescription Population (million), 2010-2017
  • Table 176: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Prescription Population (million), 2002-2010
  • Table 177: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Prescription Population (million), 2010-2017
  • Table 178: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Prescription Population (million), 2002-2010
  • Table 179: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Prescription Population (million), 2010-2017
  • Table 180: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Prescription Population (million), 2002-2010
  • Table 181: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Prescription Population (million), 2010-2017
  • Table 182: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Annual Cost of Therapy ($), 2002-2010
  • Table 183: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Annual Cost of Therapy ($), 2010-2017
  • Table 184: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Annual Cost of Therapy ($), 2002-2010
  • Table 185: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Annual Cost of Therapy ($), 2010-2017
  • Table 186: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Annual Cost of Therapy ($), 2002-2010
  • Table 187: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Annual Cost of Therapy ($), 2010-2017
  • Table 188: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Annual Cost of Therapy ($), 2002-2010
  • Table 189: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Annual Cost of Therapy ($), 2010-2017
  • Table 190: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Revenue ($bn), 2002-2010
  • Table 191: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 192: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Revenue ($bn), 2002-2010
  • Table 193: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Revenue Forecasts ($bn), 2010-2017
  • Table 194: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Revenue ($bn), 2002-2010
  • Table 195: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Revenue Forecasts ($bn), 2010-2017
  • Table 196: Immunomodulators Market to 2017, Immunostimulants, I Antibodies, ROW, Revenue ($bn), 2002-2010
  • Table 197: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Revenue Forecasts ($bn), 2010-2017
  • Table 198: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, NDA Filed, 2011
  • Table 199: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, Phase III, 2011
  • Table 200: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, Phase II, 2011
  • Table 201: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, Phase I, 2011
  • Table 202: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, Preclinical/Discovery Phase, 2011
  • Table 203: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Pharmaceutical Forms of Interferons, 2011
  • Table 204: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Prescription Population, 2002-2010
  • Table 205: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Prescription Population, 2010-2017
  • Table 206: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Prescription Population, 2002-2010
  • Table 207: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Prescription Population, 2010-2017
  • Table 208: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Prescription Population, 2002-2010
  • Table 209: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Prescription Population, 2010-2017
  • Table 210: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Revenue ($bn), 2002-2010
  • Table 211: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Revenue Forecasts ($bn), 2010-2017
  • Table 212: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Annual Cost of Therapy ($), 2002-2010
  • Table 213: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Annual Cost of Therapy ($), 2010-2017
  • Table 214: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Annual Cost of Therapy ($), 2002-2010
  • Table 215: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Annual Cost of Therapy ($), 2010-2017
  • Table 216: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Annual Cost of Therapy ($), 2002-2010
  • Table 217: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Annual Cost of Therapy ($), 2010-2017
  • Table 218: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Annual Cost of Therapy ($), 2002-2010
  • Table 219: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Annual Cost of Therapy ($), 2010-2017
  • Table 220: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Revenue ($bn), 2002-2010
  • Table 221: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 222: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Revenue ($bn), 2002-2010
  • Table 223: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Revenue Forecasts ($bn), 2010-2017
  • Table 224: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Revenue ($bn), 2002-2010
  • Table 225: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Revenue Forecasts ($bn), 2010-2017
  • Table 226: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Revenue ($m), 2002-2010
  • Table 227: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Revenue Forecasts ($m), 2010-2017
  • Table 228: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Pipeline Molecules, Phase III, 2011
  • Table 229: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Pipeline Molecules, Phase II, 2011
  • Table 230: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Pipeline Molecules, Phase I, 2011
  • Table 231: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Pipeline Molecules, Preclinical/Discovery Phase, 2011
  • Table 232: Immunomodulators Market to 2017, Roche, Marketed Products, Sales ($m), 2010
  • Table 233: Immunomodulators Market to 2017, Amgen Inc, Marketed Products, Sales ($m), 2010
  • Table 234: Immunomodulators Market to 2017, Abbott Laboratories, Marketed Products, Sales ($m), 2010
  • Table 235: Immunomodulators Market to 2017, Johnson & Johnson, Marketed Products, Sales ($m), 2010
  • Table 236: Immunomodulators Market to 2017, Novartis AG, Marketed Products, Sales ($m) 2010
  • Table 237: Immunomodulators Market to 2017, Biogen Idec, Marketed Products, Sales ($m), 2010
  • Table 238: Immunomodulators Market to 2017, Merck & Co Inc, Marketed Products, Sales ($m), 2010
  • Table 239: Immunomodulators Market to 2017, Bristol-Myers Squibb Company, Marketed Products, Sales ($m), 2010
  • Table 240: Immunomodulators Market to 2017, Eli Lilly and Company, Marketed Products, Sales ($m), 2010
  • Table 241: Immunomodulators Market to 2017, Global, Strategic Consolidations, M&A by Year, 2010-2011
  • Table 242: Immunomodulators Market to 2017, Global, Strategic Consolidations, Top Five M&A Deals by Value, 2010-2011
  • Table 243: Immunomodulators Market to 2017, Global, Strategic Consolidations, Licensing Deals by Year, 2010-2011
  • Table 244: Immunomodulators Market to 2017, Global, Strategic Consolidations, Top Five Licensing Deals by Value, 2010-2011
  • Table 245: Immunomodulators Market to 2017, Global, Strategic Consolidations, Partnership Deals by Year, 2010-2011
  • Table 246: Immunomodulators Market to 2017, Global, Strategic Consolidations, Top Five Partnership Deals by Value, 2010-2011

List of Figures

  • Figure 1: Immunomodulators Market to 2017, Immunomodulator Classification, 2011
  • Figure 2: Immunomodulators Market to 2017, Drivers and Barriers, 2011
  • Figure 3: Immunomodulators Market to 2017, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 4: Immunomodulators Market to 2017, Global, Revenue Split by Immunomodulator Class, 2010
  • Figure 5: Immunomodulators Market to 2017, Global, Annual Cost of Therapy ($), 2002-2017
  • Figure 6: Immunomodulators Market to 2017, Global, Prescription Population (million), 2002-2017
  • Figure 7: Immunomodulators Market to 2017, The US, Revenue Forecasts ($bn), 2002-2017
  • Figure 8: Immunomodulators Market to 2017, Europe, Revenue Forecasts ($bn), 2002-2017
  • Figure 9: Immunomodulators Market to 2017, ROW, Revenue Forecasts ($bn), 2002-2017
  • Figure 10: Immunomodulators Market to 2017, Immunosuppressants, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 11: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Revenue Split of Antibody Classes, 2011
  • Figure 12: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Prescription Population (million), 2002-2017
  • Figure 13: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Prescription Population (million), 2002-2017
  • Figure 14: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Prescription Population (million), 2002-2017
  • Figure 15: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Prescription Population (million), 2002-2017
  • Figure 16: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Annual Cost of Therapy ($), 2002-2017
  • Figure 17: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Annual Cost of Therapy ($), 2002-2017
  • Figure 18: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Annual Cost of Therapy ($), 2002-2017
  • Figure 19: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Annual Cost of Therapy ($), 2002-2017
  • Figure 20: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 21: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Revenue Forecasts ($bn), 2002-2017
  • Figure 22: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Revenue Forecasts ($bn), 2002-2017
  • Figure 23: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Revenue Forecasts ($bn), 2002-2017
  • Figure 24: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Prescription Population (million), 2002-2017
  • Figure 25: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US, Prescription Population, 2002-2017
  • Figure 26: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Prescription Population, 2002-2017
  • Figure 27: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Prescription Population, 2002-2017
  • Figure 28: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Annual Cost of Therapy ($), 2002-2017
  • Figure 29: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US Annual Cost of Therapy ($), 2002-2017
  • Figure 30: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Annual Cost of Therapy ($), 2002-2017
  • Figure 31: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Annual Cost of Therapy ($), 2002-2017
  • Figure 32: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 33: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US, Revenue Forecasts ($bn), 2002-2017
  • Figure 34: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Revenue Forecasts ($bn), 2002-2017
  • Figure 35: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Revenue Forecasts ($bn), 2002-2017
  • Figure 36: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Prescription Population (million), 2002-2017
  • Figure 37: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Prescription Population (million), 2002-2017
  • Figure 38: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Prescription Population (million), 2002-2017
  • Figure 39: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Prescription Population (million), 2002-2017
  • Figure 40: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Annual Cost of Therapy ($), 2002-2017
  • Figure 41: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Annual Cost of Therapy ($), 2002-2017
  • Figure 42: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Annual Cost of Therapy ($), 2002-2017
  • Figure 43: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Annual Cost of Therapy ($), 2002-2017
  • Figure 44: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 45: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Revenue Forecasts ($bn), 2002-2017
  • Figure 46: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Revenue Forecasts ($bn), 2002-2017
  • Figure 47: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Revenue Forecasts ($bn), 2002-2017
  • Figure 48: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Prescription Population, 2002-2017
  • Figure 49: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Prescription Population, 2002-2017
  • Figure 50: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Prescription Population, 2002-2017
  • Figure 51: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Prescription Population, 2002-2017
  • Figure 52: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Annual Cost of Therapy ($), 2002-2017
  • Figure 53: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Annual Cost of Therapy ($), 2002-2017
  • Figure 54: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Annual Cost of Therapy ($), 2002-2017
  • Figure 55: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Annual Cost of Therapy ($), 2002-2017
  • Figure 56: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 57: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Revenue Forecasts ($bn), 2002-2017
  • Figure 58: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Revenue Forecasts ($bn), 2002-2017
  • Figure 59: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Revenue Forecasts ($bn), 2002-2017
  • Figure 60: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Prescription Population (million), 2002-2017
  • Figure 61: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Prescription Population (million), 2002-2017
  • Figure 62: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Prescription Population (million), 2002-2017
  • Figure 63: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Prescription Population (million), 2002-2017
  • Figure 64: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Annual Cost of Therapy ($), 2002-2017
  • Figure 65: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Annual Cost of Therapy ($), 2002-2017
  • Figure 66: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Annual Cost of Therapy ($), 2002-2017
  • Figure 67: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Annual Cost of Therapy ($), 2002-2017
  • Figure 68: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 69: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Revenue Forecasts ($bn), 2002-2017
  • Figure 70: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Revenue Forecasts ($bn), 2002-2017
  • Figure 71: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Revenue Forecasts ($bn), 2002-2017
  • Figure 72: Immunomodulators Market to 2017, Immunostimulants, Revenue Forecasts ($bn), 2002-2017
  • Figure 73: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Market Share by Indication (%), 2010
  • Figure 74: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Target Pediatric and Adult Population ('000), 2002-2017
  • Figure 75: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 76: Immunomodulators Market to 2017, Immunostimulants, Vaccines, The US, Revenue Forecasts ($bn), 2002-2017
  • Figure 77: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Europe, Revenue Forecasts ($bn), 2002-2017
  • Figure 78: Immunomodulators Market to 2017, Immunostimulants, Vaccines, ROW, Revenue Forecasts ($bn), 2002-2017
  • Figure 79: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Prescription Population (million), 2002-2017
  • Figure 80: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Prescription Population (million), 2002-2017
  • Figure 81: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Prescription Population (million), 2002-2017
  • Figure 82: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Prescription Population (million), 2002-2017
  • Figure 83: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Annual Cost of Therapy ($), 2002-2017
  • Figure 84: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Annual Cost of Therapy ($), 2002-2017
  • Figure 85: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Annual Cost of Therapy ($), 2002-2017
  • Figure 86: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Annual Cost of Therapy ($), 2002-2017
  • Figure 87: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 88: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Revenue Forecasts ($bn), 2002-2017
  • Figure 89: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Revenue Forecasts ($bn), 2002-2017
  • Figure 90: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Revenue Forecasts ($bn), 2002-2017
  • Figure 91: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Prescription Population, 2002-2017
  • Figure 92: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Prescription Population, 2002-2017
  • Figure 93: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Prescription Population, 2002-2017
  • Figure 94: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Revenue Forecasts ($bn), 2002-2017
  • Figure 95: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Annual Cost of Therapy ($), 2002-2017
  • Figure 96: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Annual Cost of Therapy ($), 2002-2017
  • Figure 97: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Annual Cost of Therapy ($), 2002-2017
  • Figure 98: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Annual Cost of Therapy ($), 2002-2017
  • Figure 99: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 100: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Revenue Forecasts ($bn), 2002-2017
  • Figure 101: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Revenue Forecasts ($bn), 2002-2017
  • Figure 102: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Revenue Forecasts ($bn), 2002-2017
  • Figure 103: Immunomodulators Market to 2017, Global, Market Share Analysis by Company (%), 2010
  • Figure 104: Immunomodulators Market to 2017, Roche, SWOT Analysis, 2011
  • Figure 105: Immunomodulators Market to 2017, Amgen Inc, SWOT Analysis, 2011
  • Figure 106: Immunomodulators Market to 2017, Abbott Laboratories ,SWOT Analysis, 2011
  • Figure 107: Immunomodulators Market to 2017, Johnson & Johnson, SWOT Analysis, 2011
  • Figure 108: Immunomodulators Market to 2017, Novartis AG, SWOT Analysis, 2011
  • Figure 109: Immunomodulators Market to 2017, Biogen Idec, SWOT Analysis, 2011
  • Figure 110: Immunomodulators Market to 2017, Merck & Co Inc, SWOT Analysis, 2011
  • Figure 111: Immunomodulators Market to 2017, Bristol-Myers Squibb Company, SWOT Analysis, 2011
  • Figure 112: Immunomodulators Market to 2017, Eli Lilly and Company, SWOT Analysis, 2011
  • Figure 113: Immunomodulators Market to 2017, Global, Strategic Consolidations by Deal Type, 2010-2011
  • Figure 114: Immunomodulators Market to 2017, Global, Strategic Consolidations, M&A by Year, 2010-2011
  • Figure 115: Immunomodulators Market to 2017, Global, Strategic Consolidations, M&A by Value (%), 2010-2011
  • Figure 116: Immunomodulators Market to 2017, Global, Strategic Consolidations, M&A Deals by Geography (%), 2010-2011
  • Figure 117: Immunomodulators Market to 2017, Global, Strategic Consolidations, Licensing Deals by Year, 2010-2011
  • Figure 118: Immunomodulators Market to 2017, Global, Strategic Consolidations, Licensing Deals by Value (%), 2010-2011
  • Figure 119: Immunomodulators Market to 2017, Global, Strategic Consolidations, Licensing Deals by Geography (%), 2010-2011
  • Figure 120: Immunomodulators Market to 2017, Global, Strategic Consolidations, Partnership Deals by Year, 2010-2011
  • Figure 121: Immunomodulators Market to 2017, Global, Strategic Consolidations, Partnership Deals by Value (%), 2010-2011
  • Figure 122: Immunomodulators Market to 2017, Global, Strategic Consolidations, Partnership Deals by Geography (%), 2010-2011
  • Figure 123: GBI Research Market Forecasting Model
Back to Top